Skip to content
Mushroom Retreats
Not yet recruitingPhase 1NCT07360301

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the "trip") or from direct effects on the brain. (The sponsor's summary, shortened.)

Eligibility and contacts on ClinicalTrials.gov

The registry record

Status
Not yet recruiting
Phase
Phase 1
Conditions
Well-Being, Psychological; Psychedelic Experiences
Intervention
Psilocybin; Saline Placebo; Clonidine
Sponsor
University of Wisconsin, Madison
Ages
18 Years to 45 Years
Sex
All
Healthy volunteers
Accepted
Enrolment
120 people (planned)
Start
October 2026
Primary completion
February 2028
Registry last updated
29 September 2026

Sites (1)

  • University of Wisconsin, Madison, Wisconsin, United States

How joining a trial works

Free to take part
Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
Screened first
Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
Eligibility is strict
Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
You may get a placebo
Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
Contact the study team through the registry
Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
Not medical advice
This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications

Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.

Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials